SCHEMBL6213922

SCHEMBL6213922

N#CC(C#N)=CNNc1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ TRPA1 O75762 1/20 0.47
▸ MAPT P10636 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ CRHBP P24387 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CRHR2 Q13324 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ EGFR P00533 3/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ APBA1 Q02410 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10620620 0.87 TRPA1 (0.41) MAPK1ALDH1A1TRPA1MAPTHPGD
SCHEMBL4231741 0.84 ALDH1A1 (0.61) MAPK1ALDH1A1TRPA1MAPTHPGD
SCHEMBL10619032 0.78 TRPA1 (0.35) MAPK1ALDH1A1TRPA1MAPTMEN1
SCHEMBL10616544 0.78 GABRA1 (0.44) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL10989651 0.74 KMT2A (0.33) MAPK1ALDH1A1TRPA1KMT2AGAA
SCHEMBL10987624 0.74 KMT2A (0.33) MAPK1ALDH1A1TRPA1KMT2AGAA
SCHEMBL10990347 0.74 GAA (0.33) MAPK1ALDH1A1TRPA1GAA
SCHEMBL10992984 0.74 GAA (0.33) MAPK1ALDH1A1TRPA1GAA
SCHEMBL10991268 0.74 CXCR1 (0.34) MAPK1ALDH1A1TRPA1GAA
SCHEMBL10993202 0.74 GAA (0.47) ALDH1A1TRPA1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0748219-B8 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-06-08 — — EP disclosed
EP-0748219-B1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-04-06 — — EP disclosed
US-5981569-A CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-09 — — US disclosed
EP-0748219-A4 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 1999-06-16 — — EP disclosed
US-5849742-A Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis SUGEN INC. (US) 1998-12-15 — — US disclosed
US-5792771-A FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA SUGEN, INC. (US) 1998-08-11 — — US disclosed
US-5763441-A ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS SUGEN, INC. (US) 1998-06-09 — — US disclosed
US-5712395-A BENZO(G)QUINOXALINE YISSUM RESEARCH DEVELOPMENT CORP. (IL) 1998-01-27 — — US disclosed
EP-0748219-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS Sugen, Inc. (US) 1996-12-18 — — EP disclosed
WO-1995021613-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN, INC. (US) 1995-08-17 — — WO disclosed
Send feedback